lbpharma.us (LBRX) Earnings growth forecast for next year

LB Pharmaceuticals Inc is scaling its portfolio of drugs to combat severe mental pathologies as it concludes global trials. The consensus estimate for net profit growth rates reflects market expectations, where the current level stands at 5.60. Simultaneously, the company is implementing emission filtration systems in its laboratories to comply with ESG standards. The issuer's future revenues will be based on the market launch of innovative antipsychotics with enhanced safety profiles.

LB Pharma (LBRX): Expected net earnings per share growth next year from 09/12/2025 to 11/14/2026

Comprehensive metric breakdowns and analytics for lbpharma.us (LBRX)

- share price and consensus valuation forecast:

Stock Price LB Pharma|LBRX - Consensus Target

- market capitalization details:

Market Capitalization LB Pharmaceuticals|LBRX - Value Adjusted for Debt and Cash

- book capitalization indicators:

Net Assets per Single Share LB Pharmaceuticals|LBRX - Total Stockholders' Equity|Market Value to Book Value Ratio lbpharma.us|LBRX - Aggregate Company Assets

- company total debt and liquidity indicators:

- net income and valuation ratios data:

LBRX - Net Profit|Expected Profit LB Pharmaceuticals Inc|LBRX - Company Value to Net Income|Future Price to Earnings LB Pharmaceuticals Inc|LBRX - Price/Earnings to Growth Multiple|EV/EBITDA Multiple LB Pharmaceuticals|LBRX - Operating profit EBITDA|Net earnings per share (EPS TTM) LB Pharmaceuticals|LBRX - Net earnings per share for the last 12 months|Quarterly EPS earnings growth lbpharma.us|LBRX - Earnings per share growth rate in current year|Expected earnings per share growth for next year LB Pharmaceuticals Inc

- total revenue and sales volume data:

LBRX - Revenue and Sales Volume|Company Future Sales Volume LB Pharma|LBRX - Market Cap to Sales Volume|Forward P/S Multiple LB Pharmaceuticals

Fundamental company valuation:LBRX, LB Pharma

Finished products of LB Pharmaceuticals, Inc.

For LB Pharmaceuticals Inc (LBRX), which is developing innovative antipsychotics, the trend in consensus earnings per share (EPS) estimates reflects market optimism regarding the success of clinical trials. This metric measures the weighted average analyst expectation for future net income expressed on a per-share basis. The indicator is formed by aggregating expert forecast models that assess the potential commercialization of the drugs. While the growth of this indicator confirms fundamental attractiveness, it requires comparison with the asset's current valuation to avoid overpaying.

Who LB Pharmaceuticals Inc competes with